NO954389L - Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte - Google Patents

Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte

Info

Publication number
NO954389L
NO954389L NO954389A NO954389A NO954389L NO 954389 L NO954389 L NO 954389L NO 954389 A NO954389 A NO 954389A NO 954389 A NO954389 A NO 954389A NO 954389 L NO954389 L NO 954389L
Authority
NO
Norway
Prior art keywords
salt
squalene synthetase
synthetase inhibitor
phosphonosulfonate
inhibitor salts
Prior art date
Application number
NO954389A
Other languages
English (en)
Norwegian (no)
Other versions
NO954389D0 (no
Inventor
Yadagiri Pendri
Chung Pin Chen
David J Kucera
Eduardo J Martinez
Paul D Pansegrau
John K Thottathil
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO954389D0 publication Critical patent/NO954389D0/no
Publication of NO954389L publication Critical patent/NO954389L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
NO954389A 1994-11-03 1995-11-02 Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte NO954389L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33366194A 1994-11-03 1994-11-03

Publications (2)

Publication Number Publication Date
NO954389D0 NO954389D0 (no) 1995-11-02
NO954389L true NO954389L (no) 1996-05-06

Family

ID=23303735

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954389A NO954389L (no) 1994-11-03 1995-11-02 Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte

Country Status (14)

Country Link
EP (1) EP0710665A1 (fr)
JP (1) JPH08208672A (fr)
KR (1) KR960017680A (fr)
CN (1) CN1130188A (fr)
AU (1) AU3458795A (fr)
CA (1) CA2159850A1 (fr)
CZ (1) CZ279595A3 (fr)
FI (1) FI955256L (fr)
HU (1) HUT73140A (fr)
IL (1) IL115537A0 (fr)
NO (1) NO954389L (fr)
PL (1) PL311218A1 (fr)
TW (1) TW318852B (fr)
ZA (1) ZA959326B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
WO2002038180A1 (fr) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. Agent haute densite faisant monter le taux de lipoproteine-cholesterol
WO2007075186A2 (fr) 2005-04-18 2007-07-05 The Regents Of The University Of California Traitement antimicrobien pour infections bactériennes
JP5161872B2 (ja) 2006-05-12 2013-03-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 細菌感染に対する抗微生物療法
CN101580472B (zh) * 2009-06-24 2013-07-10 广西壮族自治区化工研究院 1,1'-联-2-萘酚的拆分剂以及拆分方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2107644A1 (fr) * 1992-10-28 1994-04-29 David R. Magnin .alpha.-phosphonosulfonates, inhibiteurs de la squalene-synthetase; methode d'utilisation
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors

Also Published As

Publication number Publication date
FI955256A7 (fi) 1996-05-04
ZA959326B (en) 1997-05-05
EP0710665A1 (fr) 1996-05-08
CA2159850A1 (fr) 1996-05-04
PL311218A1 (en) 1996-05-13
NO954389D0 (no) 1995-11-02
TW318852B (fr) 1997-11-01
FI955256L (fi) 1996-05-04
AU3458795A (en) 1996-05-09
CN1130188A (zh) 1996-09-04
CZ279595A3 (en) 1996-08-14
IL115537A0 (en) 1996-01-19
HUT73140A (en) 1996-06-28
FI955256A0 (fi) 1995-11-02
JPH08208672A (ja) 1996-08-13
KR960017680A (ko) 1996-06-17
HU9503136D0 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
EG20693A (en) Isoxazoline compounds as antiinflammatory agents
NO932620L (no) Amindiol-proteaseinhibitorer
BG102738A (en) Inhibitors of farnesyl-protein transferase
DK327689D0 (da) Diphosphonsyrederivater, fremgangsmaade til deres fremstilling og laegemidler indeholdende disse forbindelser
DK0526488T3 (da) Benzylphosphonsyre-tyrosinkinaseinhibitorer
NO972043D0 (no) Tienopyridin eller tienopyrimidinderivater og deres anvendelse
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
BR0211551A (pt) Controle de desenvolvimento de biofilmes em água de processo industrial
CA2144372A1 (fr) Composition pour le traitement de l'eau
MY112413A (en) Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
BG101717A (bg) Инхибитори на микрозомалния триглицерид пренасящ белтък и метод
EP1143957A3 (fr) Traitement de l'arthrite a l'aide d'inhibiteurs de la mek
GR3032506T3 (en) 3-aryl-2-isoxazolines as antiinflammatory agents
AP9701007A0 (en) Substituted azetidin-2-ones for treatment of atherosclerosis.
EP0401705A3 (fr) Utilisation d'un inhibiteur de l'HMG-CoA réductase et/ou d'un inhibiteur de la squalène-synthétase pour le traitement des maladies athérosclérotiques périphériques
ATE253062T1 (de) 4- und 5-alkynyloxindole sowie 4- und 5- alkenyloxindole
CA2020858A1 (fr) Methode et agent pour l'epuration de l'eau dans une chaudiere
FI953157A0 (fi) Ympärist¦lietteen käsittelymenetelmä
NO954389L (no) Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte
BR0002297A (pt) Aditivo de gênero alimentìcio que contém ácido d-pantotênico e/ou seus sais e um processo para a sua preparação
MA23790A1 (fr) Procede pour desactiver ou detruire des microorganismes
NO982081L (no) Syntetiske mineralmikropartikler og retensjonshjelpemidler og vannbehandlingssystemer og fremgangsmÕter ved anvendelse av slike partikler
DK0712278T3 (da) N-pyridyltoluidinholdigt svampedræbende, vanddispergerbart granulat
WO2000023060A8 (fr) Procede de traitement des troubles immunologiques induits par les lymphocytes t